Home/Pipeline/AVA7100

AVA7100

Not Disclosed

PreclinicalActive

Key Facts

Indication

Not Disclosed

Phase

Preclinical

Status

Active

Company

Avacta Group

About Avacta Group

Avacta Group is an AIM-listed biotech focused on developing targeted oncology therapies that improve the therapeutic index of potent cancer drugs. Its core achievement is the pre|CISION® platform, which has demonstrated a 100:1 tumor-to-plasma drug concentration ratio in clinical trials with its lead asset, AVA6000 (FAP-doxorubicin). The strategy involves evolving the platform through three generations—from rapid-release first-gen conjugates to sustained-release and dual-payload systems—to address a broad range of solid tumors (over 90% of which express FAP) and overcome resistance mechanisms. With two clinical-stage programs and a clear pipeline, Avacta aims to redefine cancer drug delivery.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active